Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on Targeted, Systemic Delivery of siRNA
Complete the form below to unlock access to ALL audio articles.
Arrowhead Research Corporation has announced that majority-owned subsidiary Calando Pharmaceuticals has published results in the Proceedings of the National Academy of Sciences (PNAS) of the first non-human primate study to use multiple, systemic dosing with Calando's lead siRNA therapeutic candidate.
Calando is using its proprietary technologies in targeted polymeric delivery systems and siRNA design to create targeted siRNA therapeutics. Its lead anti-cancer therapeutic candidate contains a linear cyclodextrin polymer, the siRNA, and a targeting agent. The formulation self assembles into nanoparticles that protect the siRNA from nuclease degradation in serum.
The Company says that one important result of the study was the lack of a significant immune response to the siRNA, demonstrating that the formulation is well tolerated at doses much higher than those previously shown to have anti-cancer effects.
